Evidence map›Paper›PMID 40162901›Full record

Trial reportJournal of primary care & community health

Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial.

Anmol Desai, Kia Reinis, Lauren O'Neal, Patrick Chang, Cristal Brown, Michael Stefanowicz, Audrey Kuang, Deepak Agrawal, Tim Mercer, Darlene Bhavnani

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05460130 (Implementation of a Simplified, Low-barrier Primary Care HCV Treatment Model for High Risk, High Prevalence Populations in Austin, Texas), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05460130 naunknown statusnot on this map

Implementation of a Simplified, Low-barrier Primary Care HCV Treatment Model for High Risk, High Prevalence Populations in Austin, Texas

TypeinterventionalSponsorUniversity of Texas at AustinRan2022 to 2023Enrolled64ConditionsHepatitis C Virus InfectionArmsSimplified Hepatitis C Virus (HCV) Treatment Protocol
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anmol DesaiThe University of Texas at Austin Dell Medical School, Austin, TX, USA.ORCID 0000-0002-3952-1896
Kia ReinisThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Lauren O'NealThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Patrick ChangThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Cristal BrownThe University of Texas at Austin Dell Medical School, Austin, TX, USA.ORCID 0000-0002-4257-8631
Michael StefanowiczThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Audrey KuangThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Deepak AgrawalThe University of Texas at Austin Dell Medical School, Austin, TX, USA.
Tim MercerThe University of Texas at Austin Dell Medical School, Austin, TX, USA.ORCID 0000-0002-8831-0569
Darlene BhavnaniThe University of Texas at Austin Dell Medical School, Austin, TX, USA.ORCID 0000-0002-4313-0089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHepatitis C virus (HCV) treatment with pan-genotypic direct acting antivirals is highly effective, given an evidence-based simplified treatment algorithm. Yet access to treatment is limited among vulnerable populations.

objectiveWe assessed the effectiveness of site-specific HCV treatment workflows on HCV care for vulnerable populations in Austin, Texas.

methodsPatients diagnosed with chronic hepatitis C enrolled in care at a study site were eligible for this prospective, single-arm clinical trial. We assessed the proportion of participants that: (1) were prescribed treatment, (2) initiated treatment, (3) completed treatment, (4) were assessed for cure, and (5) achieved cure. We also evaluated implementation using the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework.

resultsOf 62 participants, 89% had ever experienced homelessness and 94% had ever used drugs. An estimated 66% (95% CrI, 42%-84%) were prescribed treatment and 49% (95% CrI, 26%-70%) initiated treatment. An estimated 38% (95% CrI, 20%-58%) completed treatment, 14% (95% CrI, 4%-44%) were assessed for cure, and 10% (95% CrI, 2%-35%) achieved cure.

conclusionsWe identified gaps along the HCV care cascade between: (1) enrolled to prescribed treatment and (2) completed treatment to assessed for cure. Site-specific HCV treatment workflows were insufficient to engage participants in care and avoid treatment delays. Novel approaches are needed and these may include patient outreach, patient navigation, test-and-treat protocols, and removing financial or payor barriers to medication access.

trial registrationRegistered on ClinicalTrials.gov on July, 14, 2022. Identifier: NCT05460130. https://clinicaltrials.gov/ct2/show/NCT05460130.

Indexed as

Antiviral AgentsHepatitis C, ChronicVulnerable PopulationsWorkflowAdultFemaleHepacivirusHumansIll-Housed PersonsMaleMiddle AgedProspective StudiesTexasAntiviral Agentshepatitis Cimplementation researchpeople experiencing homelessness (PEH)people who inject drugs (PWID)primary care

Identifiers

PMID40162901
PMCPMC11960160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.